Back to top
more

Cerner Corporation (CERN)

(Delayed Data from NSDQ)

$68.47 USD

68.47
2,167,881

+0.46 (0.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $68.46 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Accuray (ARAY) Q2 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Accuray (ARAY) registers growth in Products revenues during fiscal Q2, thereby partly driving its overall top line.

NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View

by Zacks Equity Research

NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strength in both of its revenue sources.

Here's Why You Should Invest in Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein's (HSIC) strong segmental performance and raised 2021 EPS guidance.

Cerner (CERN) Stock Moves -0.37%: What You Should Know

by Zacks Equity Research

Cerner (CERN) closed the most recent trading day at $91.37, moving -0.37% from the previous trading session.

Veeva Systems (VEEV)-LYSARC Partner to Advance Lymphoma Therapy

by Zacks Equity Research

Veeva Systems' (VEEV) Veeva Development Cloud will allow LYSARC to develop innovative lymphoma therapies or enhance current therapies.

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.

BD (BDX) Hits a New 52-Week High: What's Behind the Rally?

by Zacks Equity Research

A slew of strategic acquisitions are driving the top line for BD (BDX).

OPKO's (OPK) NGENLA Approved by Japan's MHLW for GHD Treatment

by Zacks Equity Research

Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.

Nevro's (NVRO) Senza Gets FDA Nod for Expanded Labeling for NSRBP

by Zacks Equity Research

Nevro's (NVRO) receipt of the FDA's approval for expanded labeling of its Senza SCS System is expected to cater to underserved patients.

3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

Catalent (CTLT) to Advance Oral Drug Development With New Launch

by Zacks Equity Research

Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.

PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues

by Zacks Equity Research

PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.

AMN Healthcare (AMN) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

AMN Healthcare's (AMN) solid fourth-quarter results are likely to have been boosted by solid segmental performances.

Here's Why You Should Retain Cigna (CI) in Your Portfolio

by Zacks Equity Research

Cigna (CI) is well-poised for growth, attributable to solid segmental contributions, the continuous launch of affordable MA plans, a strong partner network and sufficient cash reserves.

Masimo (MASI) Provides FY22 View, Preliminary FY21 Results Solid

by Zacks Equity Research

Masimo's (MASI) solid full-year results likely to have been boosted by strong product sales.

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

by Zacks Equity Research

Investors remain optimistic about Abiomed (ABMD) due to its Impella product line's strength.

Inogen's (INGN) Preliminary Q4 Revenues Solid Amid Challenges

by Zacks Equity Research

Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by solid product sales despite supply chain constraints.

Here's Why You Should Retain BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about BD (BDX) owing to its slew of regulatory approvals and strategic buyouts.

Quidel Corporation (QDEL) Reports Solid Preliminary Q4 Revenues

by Zacks Equity Research

Quidel's (QDEL) revenue growth in the fourth quarter is likely to have been boosted by continued robust sales of its SARS-related products.

Cerner (CERN) Stock Moves -0.1%: What You Should Know

by Zacks Equity Research

Cerner (CERN) closed at $92.55 in the latest trading session, marking a -0.1% move from the prior day.

Walgreens Boots (WBA) Gains From New Pacts, Faces Margin Woes

by Zacks Equity Research

Of late, increased reimbursement pressure and generic drug cost inflation have been hampering Walgreens Boots' (WBA) margins significantly.

Abbott's (ABT) Proclaim XR SCS Gets FDA Nod for New MRI Label

by Zacks Equity Research

The latest FDA approval is set to augment Abbott's (ABT) Neuromodulation arm, which is having a hard time amid the COVID spell due to its elective nature of business.

Zacks.com featured highlights include: Boston Beer Co. Inc., Williams-Sonoma, Inc., Cerner Corp., PNM Resources and Sonoco Products Co

by Zacks Equity Research

Boston Beer Co. Inc., Williams-Sonoma, Inc., Cerner Corp., PNM Resources and Sonoco Products Co are highlighted in this screen of the week article.

Quest Diagnostics (DGX) Rides on Test Sales, Base Volume Gain

by Zacks Equity Research

Quest Diagnostics (DGX) continues to benefit from rapidly increasing molecular diagnostic testing volumes, driven by the massive spread of the new COVID-19 variant.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) given the strength in the diagnostics business and notable acquisition deals.